Potential new biomarkers for endometrial cancer

Michelle H. Townsend1, Zac E. Ence2, Abigail M. Felsted1, Alyssa C. Parker2, Stephen R. Piccolo2,3, Richard A. Robison1 and Kim L. O’Neill1*

Abstract

Background: Incidence of endometrial cancer are rising both in the United States and worldwide. As endometrial cancer becomes more prominent, the need to develop and characterize biomarkers for early stage diagnosis and the treatment of endometrial cancer has become an important priority. Several biomarkers currently used to diagnose endometrial cancer are directly related to obesity. Although epigenetic and mutational biomarkers have been identified and have resulted in treatment options for patients with specific aberrations, many tumors do not harbor those specific aberrations. A promising alternative is to determine biomarkers based on differential gene expression, which can be used to estimate prognosis.

Methods: We evaluated 589 patients to determine differential expression between normal and malignant patient samples. We then supplemented these evaluations with immunohistochemistry staining of endometrial tumors and normal tissues. Additionally, we used the Library of Integrated Network-based Cellular Signatures to evaluate the effects of 1826 chemotherapy drugs on 26 cell lines to determine the effects of each drug on HPRT1 and AURKA expression.

Results: Expression of HPRT1, Jag2, AURKA, and PGK1 were elevated when compared to normal samples, and HPRT1 and PGK1 showed a stepwise elevation in expression that was significantly related to cancer grade. To determine the prognostic potential of these genes, we evaluated patient outcome and found that levels of both HPRT1 and AURKA were significantly correlated with overall patient survival. When evaluating drugs that had the most significant effect on lowering the expression of HPRT1 and AURKA, we found that Topo I and MEK inhibitors were most effective at reducing HPRT1 expression. Meanwhile, drugs that were effective at reducing AURKA expression were more diverse (MEK, Topo I, MELK, HDAC, etc.). The effects of these drugs on the expression of HPRT1 and AURKA provides insight into their role within cellular maintenance.

Conclusions: Collectively, these data show that JAG2, AURKA, PGK1, and HRPT1 have the potential to be used independently as diagnostic, prognostic, or treatment biomarkers in endometrial cancer. Expression levels of these genes may provide physicians with insight into tumor aggressiveness and chemotherapy drugs that are well suited to individual patients.

Keywords: AURKA, Biomarkers, Endometrial cancer, HPRT1, JAG2, PGK1

*Correspondence: kim_oneill@byu.edu
1 Department of Microbiology and Molecular Biology, Brigham Young University, 3142 LSB, Provo, UT 84602, USA
Full list of author information is available at the end of the article

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Endometrial cancer is the fourth most common cancer in women with 12,990 new diagnoses and 4120 deaths in 2016 in the United States [1]. Over 710,200 women are living with endometrial cancer in the United States, and approximately 2.8% of women will be diagnosed with the disease at some point during their lifetime. As the most significant risk factor for endometrial cancer is obesity, a majority of the biomarkers used to detect and monitor endometrial cancer development are related to metabolic and endocrine alterations [2]. Androgens, estrogens, prolactin, thyroid stimulating hormone, leptin, and adiponec tin are a few of the biomarkers utilized to highlight risk of endometrial cancer development. While these biomarkers can be useful, they are oftentimes somewhat subjective as the levels of these hormones fluctuate naturally, are generally elevated with obesity, and are not necessarily unique to cancer development [2, 3]. In order to find new biomarkers that may act as diagnostic biomarkers for endometrial cancer, we evaluated Jagged2 (JAG2), Aurora Kinase A (AURKA), Phosphoglycerate Kinase 1 (PGK1), and Hypoxanthine Guanine Phosphoribosyltransferase 1 (HPRT1) for their role in cellular proliferation and cancer development. We evaluated these genes because of their upregulation and diagnostic potential in other cancer types [4–9].

JAG2 is a notch transmembrane ligand. Notch signaling is a conserved signaling pathway linked to the development of several cancers due to its role in cell fate, cellular proliferation regulation, and cell death [10]. This is exemplified by the fact that Notch signaling regulates stem cell proliferation and differentiation [11]. Within cancer, Notch signaling mediates hypoxia, invasion, and chemoresistance [12], and JAG2 expression in primary tumors has been correlated with vascular development and angiogenesis [13]. In addition, elevated levels of JAG2 result in significant chemoresistance, and when JAG2 is knocked down in mice, tumor cells become sensitive to chemotherapeutics (doxorubicin) [8]. Notch signaling has been identified as an important pathway for carcinogenesis of the endometrium [14]. Additionally, JAG2 has been shown to be a promising target in several cancer cell lines, as specific antibody–drug conjugates have resulted in tumor reduction [15].

AURKA is a cell-cycle regulated kinase that functions in spindle formation and chromosome segregation during the M phase of the cell cycle. AURKA has been shown to be a downstream target of MAPK1, which is a major force in cellular proliferation in several cancer cells [16]. The protein is also elevated in a variety of cancers and has a significant association with disease recurrence [6, 7]. Because AURKA is upregulated in cancers, efforts have been made to target the protein to aid in tumor reduction. Upon AURKA suppression, cancer cells become sensitive to chemotherapeutics and overall tumor growth is suppressed in a variety of cancer cells (docetaxel and taxane) [17, 18]. The role AURKA may play as a diagnostic biomarker in endometrial cancer has not been well studied, although it has shown promising results in other cancer types [6, 7, 19–21].

PGK1 is involved in the glycolysis pathway and functions by transferring a phosphate group from 1,3-bisphosphoglycerate to ADP to form ATP [22, 23]. As an enzyme involved in generating valuable energy for the cell, especially in hypoxic conditions, PGK1 has been correlated with cancer development and progression in a variety of tumor types [9, 24, 25]. Its role in promoting tumor proliferation is linked to PGK1’s ability to promote tumor angiogenesis [26, 27], DNA replication and repair [28, 29], and cancer metastasis [25, 30]. While the protein is elevated internally in several cancers, it is also actively secreted from tumor cells, where it cleaves plasminogen to create angiostatin [31]. PGK1 has been shown to be upregulated in several cancer types, but has not been evaluated for upregulation in endometrial cancer [25, 32].

HPRT1 is a nucleotide salvage enzyme involved in the cell cycle [33, 34]. This enzyme is a transferase responsible for producing guanine and inosine nucleotides by transferring a phosphoribose from PRPP to guanine and inosine bases, respectively, during cellular maintenance [35, 36]. As cells rapidly divide, the need for nucleotides increases, and subsequently HPRT1, has been shown to be elevated in several malignant settings [4, 37]. As the enzyme shows upregulation in malignant tissue while maintaining stable levels in normal tissue, it has the potential to be used as a biomarker for cancer development in several cancer types.

Table 1 Protein expression within patient tissue

| Protein | n  | General function                  | Average gray value malignant | Average gray value CAT   | Average gray value normal |
|---------|----|-----------------------------------|------------------------------|--------------------------|---------------------------|
| HPRT    | 68 | Nucleotide salvage                | 157.206                      | 186.176                  | 223.207                   |
| PGK1    | 71 | Glycolytic enzyme                 | 107.273                      | 154.437                  | 171.748                   |
| AURKA   | 72 | Cycle-regulated kinase            | 209.994                      | 236.147                  | 244.352                   |
| Jag2    | 72 | Protein coding                    | 143.635                      | 194.297                  | 186.269                   |

*CAT cancer adjacent tissue*
We decided to evaluate these enzymes in endometrial cancer because they have all shown promising diagnostic potential in other tissue types as biomarkers for disease development and progression but have not been evaluated in endometrial cancer. As malignant endometrial biomarkers are less established, we hope to identify additional markers for malignancy to aid in the early diagnosis and possible treatment of endometrial cancer.

**Materials and methods**

**Chemicals/reagents**

DIVA Decloaker 10x, Background Sniper, Mach 4 HRP polymer, DAB Peroxidase, Hematoxylin, Hydrophobic pen, and Universal Negative antibodies were all obtained from Biocare Medical, Concord, CA. Anti-JAG2 (LifeSpan Biosciences, Inc. Seattle, USA), Anti-AURKA (Sigma-Aldrich, St. Louis, USA), and anti-PGK1 (Abcam,
Fig. 2. Tissue evaluation of AURKA, JAG2, PGK1, and HPRT. Tissues were quantified on a gray scale with lower values indicating darker staining intensity. 

a AURKA expression and 

b JAG2 expression was significant between malignant and normal samples, but showed no significance between cancer grade. 

c PGK1 expression and 

d HPRT expression showed significance both between normal and malignant samples in addition to between cancer grade.
Cambridge, UK) were stored at −20 °C. Anti-HPRT monoclonal antibody (Abcam, Cambridge, UK) was aliquoted and stored at −20 °C. GAPDH polyclonal antibody (Cell signaling) was aliquoted and stored at −20 °C. Tween20 (Fisher Reagents, Waltham MA) was stored at room temperature. Hydrogen Peroxide at 30% (Fisher Reagents, Waltham MA) was stored at 4 °C.

Tissue microarray samples
Tissue microarrays were obtained from Biomax and stained for GAPDH, HPRT, JAG2, AURKA, PGK1, and with an isotype control. Patients were all female and ranged in age from 21 to 63. Normal (n = 9), cancer adjacent (n = 9), and malignant tissue (n = 54) (grade 1–3) were included in the analysis (Table 1).

Immunohistochemistry
Protein levels were assessed using protocols described by Townsend et al. with slight modifications [4]. Briefly, tissues were rehydrated, washed, and treated with DIVA Decloaker. Following a hydrogen peroxide wash, tissues were treated with a Background Sniper followed by a primary antibody (1:100 dilution). After a series of washes, the tissues were treated with DAB Peroxidase and hematoxylin and imaged using a standard light microscope.
Tissue quantification

ImageJ software was utilized to quantify staining intensity [38]. An IHC toolbox plugin was selected with the “DAB (more brown)” option to remove staining that did not result from DAB. After this modification, the images were converted to a grayscale and a threshold was applied to eliminate areas of negative space that could potentially bias the results. Once a universal threshold was applied, the average gray intensity of the tissue was collected.

Survival was calculated using a Cox proportional hazard model. In addition to gene expression (primary variable), covariates included gene expression and clinical factors such as age, race, and tumor purity. Kaplan–Meier curves were generated to compare survival of patients with the highest 20% of target gene expression against those with the lowest 20% of target gene expression. The statistical analyses and curve generations were calculated utilizing the TIMER program developed by Li et al. [40].

Drug response analyses

We evaluated the effects of chemotherapy treatments on cell lines using two publicly available databases. First, we examined data from the Cancer Cell Line Encyclopedia (CCLE) [41]. We obtained treatment-response data for 24 drugs that were available from the CCLE portal and used
Cell lines were ranked according to their gene expression level (transcripts per million) and the 10 highest expressing and 10 lowest expressing cell lines are shown.

Drug responses of cell lines with elevated JAG2. The 20 cell lines with the highest and lowest expression for each target gene from the previous analysis in Fig. 6 (X-axis) were evaluated via their Activity Area (ActArea) in response to drug treatments. Drug responses are represented by individual graphs with the mean ActArea plotted on the Y-axis. Drugs with a high ActArea indicate sensitivity, while drugs with a low ActArea indicate resistance. The mean ActArea is represented by a line within the figure to indicate the average increase or reduction between the high expressing and low expressing cell lines.
the area above the fitted dose–response curve (ActArea) as a metric of treatment response [42]. We obtained transcript-level expression levels for CCLE [43] and summed protein-coding transcript values to gene-level values using a custom Python script (https://python.org). For each of four genes (HPRT1, AURKA, JAG2, and PGK1), we identified cell lines for which drug-response and gene-expression data were available and then ranked the cell lines according to expression of the respective genes. Next, we selected the lowest- and highest-expressing cell lines for each gene and used a Mann–Whitney U test to evaluate differences in ActArea values between these cell-line groups. To perform these calculations, we used the R statistical software (version 3.4.3) [44].

Second, we evaluated data from the Library of Integrated Network-based Cellular Signatures, which contains gene-expression profiles for cell lines after drug perturbations. We wrote a Python (version 3.6.5) script to extract HPRT1 and AURKA expression values from the LINCS database for samples from 26 cell lines for which data were available. We used the Level 5 data, which were generated using the L1000 platform [45], normalized using a z-score methodology within each plate, and averaged across replicates. Using the R (version 3.4.4) [44] statistical software and the readr package (version 1.1.1) [46], we parsed the metadata file to identify experiments where the cell lines had been treated with chemotherapeutic compounds (pert_type=“trt_cp”). The summarized data values indicate relative gene-expression levels for cells treated with a given compound relative to control-treated cells. To perform this filtering and data transformation, we used the dplyr (version 0.7.4) [47] and reshape2 (version 1.4.3) packages [48]. Before plotting the data, we grouped the values for each cell line by compound name. We identified the median value for each group and sorted the values from lowest to highest. Then we used the superheat package (version 1.0.0) to create heatmaps with data from the 7 cell lines with the most treatment data [49]. The code and data we used for this analysis can be found at https://bitbucket.org/alyssaparker99/lincs-heatmaps.

**Statistical analysis**

Staining intensities between tissue samples were analyzed using an ANOVA test with the multiple comparison method. Additionally, unpaired t tests were utilized in conjunction to confirm statistical significance. These statistical tests were performed in GraphPad Prism 7 software. Differences were considered significant when the p value was < 0.05. Asterisks were used in figures to indicate levels of significance with ns=p>0.5, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001.

**Results**

JAG2, AURKA, PGK1, and HPRT1 had significant upregulation in malignant samples when compared to normal

We evaluated gene-expression levels for AURKA, JAG2, HPRT1, and PGK1 in tumors and normal tissues from TCGA. Upon comparing malignant and normal samples, we observed a consistent elevation of each of the genes in malignant tissues (Fig. 1). JAG2 had the smallest elevation overall (p-value = 4.6 × 10−3), while AURKA showed the largest increase (p-value = 1.2 × 10−21). This upregulation indicates that these genes may be useful as diagnostic markers of endometrial cancer, as they have differential expression between normal and malignant samples.

When analyzing protein levels in tissue microarrays from a separate cohort, we again found that all four genes were significantly elevated within malignant samples (Fig. 2). This confirmed the initial analysis with gene expression data. In addition, we found that PGK1 and HPRT1 both showed significant differences between grades as there was a stepwise elevation of protein expression corresponding to grade. This indicates that HPRT1 and PGK1 may have a grade dependency, and could serve as biomarkers for tumor aggressiveness. All four genes showed a range of protein expression in both malignant and normal samples (Fig. 3).

To determine whether elevated expression of these genes occurred in the same patients, we plotted expression values for each patient jointly for all four genes. There was no pattern of concordant elevation across PGK1, AURKA, JAG2, and HPRT1. For example, patients with elevated levels of AURKA did not share the same high levels of HPRT1 or of any of the other genes (Fig. 4). This was observed in all cancer stages. For example, there were
cases where the patient with the lowest expression of AURKA (patient 7 in Stage 2) also had the highest expression of HPRT1. This indicates that these biomarkers may be useful in identifying different patients and that each biomarker may be independently used to benefit further characterization of individual patient cancer types.

**AURKA and HPRT1 elevation have a significant impact on patient survival**

We evaluated overall patient survival in patients with the highest 20% of biomarker expression and patients with the lowest 20% biomarker expression to determine whether the elevation of these genes had any impact on survival. Both PGK1 ($p$-value = 0.589) and JAG2 ($p$-value = 0.46) showed insignificant differences between survival over the course of 100 months between high and low expressors. While there may have been elevation of these genes within cancer, they did not seem to contribute to survival outcomes. Interestingly, both AURKA and HPRT1 showed significant differences between survival in high vs low expressing patients. Following 100 months, patients with the highest 20% of AURKA expression showed significant ($p$-value < 0.0001) decreases in survival and AURKA elevation correlated with lower survival rates (Fig. 5). This same pattern was also observed for patients with elevated HPRT1 expression, as patients with the highest 20% HPRT1 expression had significantly ($p$-value = 0.041) decreased survival compared to their lower expressing counterparts. This shows that both AURKA and HPRT1 may have significance beyond diagnostic; they also may be useful, as prognostic biomarkers for uterine corpus endometrial cancer.

**Drug treatments of cell lines with high and low target gene expression**

To determine whether these genes could be utilized as biomarkers for physicians when deciding treatment options, we analyzed the effects of 24 drugs on cell lines with relatively high and low expression of AURKA, JAG2, PGK1, and HPRT1. Cell lines were ranked according to their expression of each gene and highest and lowest expressing cell lines were chosen for analysis (Fig. 6). Although there was no significance observed, there were some responses that appeared to have a larger impact than others. Drugs with the largest differences were PD-0325901 (MEK inhibitor), TAE684 (ALK inhibitor), AEW541 (IGF-1R inhibitor), and Nilotinib (tyrosine kinase inhibitor) in JAG2, PGK1, HPRT1, and AURKA, respectively. Several of the drug responses were negligible as the mean ActArea was almost identical in a majority of the responses between the high and low expression cell lines (Figs. 7, 8, 9, 10).

**Drugs with the largest impact on AURKA and HPRT1 expression**

As HPRT1 and AURKA elevation showed prognostic significance (Fig. 5), we analyzed data from the LINCS, a publicly available resource that contains gene-expression response signatures for 1826 chemotherapy drugs and 26 cell lines. We searched for drug treatments that caused significant declines in HPRT1 and/or AURKA expression. These responses varied widely across drug treatments and cell lines with some drugs increasing the expression of the genes and, others decreasing expression. The vast majority of drug treatments had no impact on HPRT1 or AURKA expression. We focused on seven cell lines for which data were most available (Fig. 11). For both genes, over 12,000 drug-cell line interactions resulted in no effect. When evaluating AURKA expression, 78 interactions resulted in a severe reduction, 396 resulted in an intermediate reduction, while 14 resulted in a severe elevation and 141 resulted in an intermediate elevation of the gene. When evaluating HPRT1 expression, 13 interactions resulted in a severe reduction, 233 resulted in an intermediate reduction, while 15 resulted in an intermediate elevation of the gene (Table 2). This indicates that AURKA may be a better prognostic biomarker than HPRT1 as there is a larger number of events where the protein was significantly decreased upon treatment.

The 10 drugs that produced the largest reduction in AURKA expression were Ro-4987655, Genz-644282,
OTS-167, Vorinostat, Pralatrexate, Epirubicin, Ro-4987655, Pralatrexate, JNJ-26481585, and R-547. Each of these drugs has a different mechanism of action but most were involved in DNA synthesis and regulation. Of note, when analyzing the drugs that resulted in an increase in AURKA expression, we found that 9 of 10 drugs were directly involved in inhibiting microtubule function or inhibited PLK. This was consistent throughout our analysis and indicates AURKA may be connected in a regulatory fashion to these cellular mechanisms (Table 3).

Drugs that resulted in the highest reduction in HPRT1 expression were AS-703026, OTS-167, BGT-226, genz-644282, AS-703026, SN-38, SN-38, TAK-733, paclitaxel, and KX2-391. Of these, six were of either Topoisomerase I (Topo I) or MEK. This may indicate a relationship between HPRT1 regulation and regulation of Topo I or the MEK pathway (Table 4).

**Discussion**
We have determined that there is a significant elevation of JAG2, HPRT1, AURKA, and PGK1 expression in endometrial cancer. With elevated expression upon malignancy, these genes can be utilized as a companion diagnostic tool to both identify and characterize endometrial cancer. As cancer specific biomarkers, these genes may serve as useful markers when analyzing endometrial cancer development within patient tissue. Additionally, HPRT and PGK1 show additional promise as possible biomarkers for cancer grade as the levels of the proteins elevated in a stepwise manner with higher cancer grade. These biomarkers have already shown utility in other cancer types [4–6, 8, 9, 16] and we have shown that their use may also extend to endometrial cancer.

While there are several epigenetic biomarkers for endometrial cancer (p52, KRAS, VEGF. PTEN, etc.)
[50, 51], there remains a need to find suitable protein biomarkers for not only endometrial diagnosis, but also as possible targets for future therapies. Future directions to this work include evaluating a larger cohort of patients to determine whether the expression of these biomarkers could have clinical application. Especially in the case of both HPRT1 and AURKA, it may be beneficial to develop therapies to reduce their expression, thereby determining whether these genes play a critical role in cancer survival and proliferation as they show significant impact on overall patient survival.

In addition, the conserved pathways that HPRT1 and AURKA have in terms of drugs that inhibit or induce their expression, may indicate a regulatory relationship between the inhibited pathway and the proteins that have not yet been identified. The merit of this hypothesis is demonstrated as AURKA has a reciprocal regulation with PLK1 in mitotic entry and within spindle assembly [52]. This corresponds to the data we have observed as the drugs with the largest impact on AURKA elevation with the highest consistency are inhibitors of PLK1 and microtubule formation. Yet, the consistent relationship between drugs that inhibit HPRT1 expression are both inhibitors of Topo I and the MEK pathway. There has not been any investigation into the relationship between HPRT1 and these proteins/pathways and our initial data show that a possible link exists. With this in mind, this potential relationship merits further examination and could potentially elucidate novel gene interactions specific to cancer.

**Conclusions**

We have determined genes with differential gene expression within endometrial cancer that also have a significant impact on overall patient survival. These biomarkers could be developed into a companion diagnostic tool in the identification and classification of endometrial cancer. In addition, they may aid in drug determination as certain drugs have a better response rate in patients with elevated levels of both AURKA and HPRT1.

**Authors’ contributions**

MHT created the concepts and designs of the experiments, carried out the acquiring and analysis of data and drafted the manuscript. ZE performed the bioinformatic analysis of expression in addition to the analysis of different chemotherapy drugs. AF carried out the IHC staining. AP did the bioinformatic analysis on the response of cell lines to various drugs. SP aided in the bioinformatic statistical evaluation and conceptual design and in manuscript revisions. RR was involved in the manuscript revisions. KO participated in the study design and revision of the manuscript. All authors read and approved the final manuscript.

**Table 4 Effective drugs for the reduction of HPRT1**

| Cell line | Drug         | Inhibition target               | Target symbol | PTEZ score |
|-----------|--------------|---------------------------------|---------------|------------|
| HT29      | AS-703026    | Mitogen-activated protein kinase | MEK           | − 9.822    |
| HUES3     | OTS-167      | Maternal embryonic leucine-zipper kinase | MEK          | − 9.707    |
| Jurkat    | BGT-226      | Phosphoinositide 3-kinase       | PI3K          | − 8.533    |
| MCF7      | genz-644282  | Topoisomerase I                 | Topo I        | − 7.601    |
| A375      | AS-703026    | Mitogen-activated protein kinase | MEK           | − 7.119    |
| MCF7      | SN-53        | Topoisomerase I                 | Topo I        | − 6.904    |
| A375      | SN-38        | Topoisomerase I                 | Topo I        | − 6.702    |
| HT29      | TAK-733      | Mitogen-activated protein kinase | MEK           | − 6.594    |
| MCF7      | Paclitaxel   | Microtubule function            | MEK           | − 6.537    |
| MCF7      | KX2-391      | Sarcome                         | − 6.366       |

**Drugs with an increase in HPRT1 expression post treatment**

| Cell line | Drug         | Inhibition target               | Target symbol | PTEZ score |
|-----------|--------------|---------------------------------|---------------|------------|
| MNEU      | Dinaciclib   | Cyclin dependent kinase         | CDK           | 2.362      |
| NPC       | SB-939       | Histone deacetylase             | HDAC          | 2.39       |
| MNEU      | Mitoxantrone | Topoisomerase II                | Topo II       | 2.412      |
| NEU       | Ischemin     | PS3 transcription               | −             | 2.454      |
| ASC       | Mitoxantrone | Inflammation                    | −             | 2.551      |
| NEU       | NVP-BG398    | Fibroblast growth factor receptor | FGFR          | 2.668      |
| Jurkat    | Tanespimycin | Heat shock protein              | HSP           | 2.72       |
| SKL       | Dinaciclib   | Cyclin dependent kinase         | CDK           | 3.137      |
| ASC       | Dinaciclib   | Cyclin dependent kinase         | CDK           | 3.195      |
| Jurkat    | Dinaciclib   | Cyclin dependent kinase         | CDK           | 5.414      |

**PTEZ post-treatment expression z-score**
Author details
1. Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA. 2. Department of Biology, Brigham Young University, Provo, UT, USA. 3. Department of Biomedical Informatics, University of Utah, Salt Lake City, UT 84132, USA.

Acknowledgements
We would like to thank the Simmons Center for Cancer Research for the financial support to conduct this research.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets supporting the conclusions of this study and included in this article. Any request for data or material can be sent to the corresponding author.

Consent to publish
Not applicable.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Funding
This research was supported by the Department of Microbiology and Molecular Biology, the College of Life Sciences, and the Simmons Center for Cancer Research.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 13 November 2018 Accepted: 8 January 2019
Published online: 21 January 2019

References
1. Siegel RL, Miller KD, Jermal A. Cancer statistics. CA Cancer J Clin. 2016;66:7–30.
2. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009;114:121–7. https://doi.org/10.1016/j.ygyno.2009.03.039.
3. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk. Cancer Epidemiol Prev Biomarkers. 2002;11:1531–43.
4. Townsend MH, Felted AM, Ence ZE, Piccolo SR, Robison RA, O’Neill KL. Elevated expression of hypoxanthine guanine phosphoribosyltransferase within malignant tissue. Cancer Clin Oncol. 2017;6:19.
5. Townsend MH, Robison RA, O’Neill KL. A review of HPRT and its emerging role in cancer. Med Oncol. 2018;35:89.
6. Goos JACM, Coupe VMH, Diosoado B, Delis-Van Diemen PM, Karga C, Beeliën JAM, et al. Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. Br J Cancer. 2013;109:3445–52. https://doi.org/10.1038/bjc.2013.608.
7. Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, et al. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia. 2009;11:418–25.
8. Vaish V, Kim J, Shim M. Jagged-2 (JAG2) enhances tumorigenicity and che moreresistance of colorectal cancer cells. Oncotarget. 2017;8:53262–75.
9. Ai J, Huang H, Lu X, Tang Z, Chen M, Chen T, et al. FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. Cell Physiol Biochem. 2011;27:207–16.
10. Sasnauskienė A, Jonušienė V, Krikštaponienė A, Butkyte S, Dabkevičienė D, Kanopiene D, et al. NOTCH1, NOTCH3, NOTCH4, and JAG2 protein levels in human endometrial cancer. Medicina. 2014;50:14–8.
11. Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369:20–7. https://doi.org/10.1016/j.canlet.2015.07.048.
12. Zou J, Li P, Fu L, Liu N, Dai J, Ye J, et al. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2013;6:1–13.
13. Petrias A, von Stedingk K, Lindgren D, Pählman S, Axelsson H. JAG2 induction in hypoxic tumor cells alters Notch signaling and enhances endothelial cell tube formation. Mol Cancer Res. 2011;9:626–36.
14. Jonušienė V, Sasnauskienė A, Lachie N, Kanopiene D, Dabkeviciene D, Sasnauskiene S, et al. Down-regulated expression of Notch signaling molecules in human endometrial cancer. Med Oncol. 2013;30:438.
15. Sagert J, West J, Wong C, Desnoyers L, Vasiljeva O, Richardson J, et al. Abstract 2665: Transforming Notch ligands into tumor-antigen targets: a Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2. Cancer Res. 2014;74:2665.
16. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene. 2006;25:4831–9.
17. He W, Zhang MG, Wang XJ, Zhong S, Shao Y, Zhu Y, et al. AURKA suppression induces Dl145 apoptosis and sensitizes Dl145 to docetaxel treatment. Am J Transl Res. 2013;5:359–67.
18. Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, et al. RNA interference targeting aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005;65:899–905.
19. Reis-Filho JS, Puszta L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378:1812–23.
20. Lassmann S, Shen Y, Jutting U, Wehsle P, Walch A, Gitsch G, et al. Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res. 2007;13:4083–91. https://doi.org/10.1158/1078-0432.CCR-06-2775.
21. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. https://doi.org/10.1056/NEJMoa02196.
22. Sun S, Liang X, Zhang X, Liu T, Shi Q, Song Y, et al. Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. Br J Cancer. 2015;112:1332–9.
23. Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, et al. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res. 2007;67:149–59.
24. Hwang T-L, Liang Y, Chien K-Y, Yu J-S. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics. 2006;6:2259–72. https://doi.org/10.1002/ pmic.200500345.
25. Zieker D, Konigsrainer I, Weinreich J, Beckert S, Glätzel J, Nieselt K, et al. Phosphoglycerate kinase 1 promotes tumor progression and metastasis in gastric cancer-detected in a tumor mouse model using positron emission tomography/magnetic resonance imaging. Cell Physiol Biochem. 2010;26:47–54.
26. Lay AJ, Jiang XM, Kisker O, Flynn E, Underwood A, Condron R, et al. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature. 2000;408:69–73.
27. Choucane L, Kabbage M, Chaheed K, Hamrta B, Guillier CL, Trieume M, et al. Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry. J Biomed Biotechnol. 2008. https://doi.org/10.11021/2008/mic.002.
28. Vishwanatha JK, Jindal HK, Davis RG. The role of primer recognition in colorectal cancer. J Cell Sci. 1992;101(Pt 1):25–34.
29. Popanda O, Fox G, Thielmann HW. Modulation of DNA polymerases α, δ and ε by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim Biophys Acta Gene Struct Expr. 1998;1397:102–17.
30. Zieker D, Konigsrainer I, Tzschichler I, Löffler M, Traub F, Nieselt K, et al. Dissemination in gastric cancer. Cancer. 2011;126:1513–20.
31. Wang J, Ying G, Wang J, Jung Y, Lu J, Zhu J, et al. Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res. 2010;70:471–80.

32. Bando H, Toi M, Kitada K, Koike M. Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed Pharmacother. 2003;57:333–40.

33. Torres RJ, Puig JG. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007;2:48.

34. Monnat RJ, Chiaverotti TA, Hackmann AF, Maresh GA. Molecular structure and genetic stability of human hypoxanthine phosphoribosyltransferase (HPRT) gene duplications. Genomics. 1992;13:788–96.

35. Wilson JM, Stout JT, Davidson BL, Kelley WN, Caskey CT. A molecular survey of hypoxanthine-guanine phosphoribosyltransferase deficiency in man. J Clin Invest. 1986;77:188–95.

36. Stout JT, Caskey CT. Hprt: gene structure, expression, and mutation. Annu Rev Genet. 1985;19:127–48.

37. Townsend MH, Anderson MD, Weagel EG, Velazquez EJ, Weber KS, Robison RA, et al. Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane. Onco Targets Ther. 2017;10:1921–32.

38. Schindelin J, Rueden CT, Hiner MC, Eliceiri KW. The ImageJ ecosystem: an open platform for biomedical image analysis. Mol Reprod Dev. 2015;82:158–29. https://doi.org/10.1002/mrd.22489.

39. Rahman M, Jackson LK, Johnson WE, Li DY, Bild AH, Piccolo SR. Alternative preprocessing of RNA-sequencing data in the Cancer Genome Atlas leads to improved analysis results. Bioinformatics. 2015;31:3666–72.

40. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–10.

41. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.

42. Jang IS, Neto EC, Guinney J, Friend SH, Margolin AA. Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. In: Pac. Symp. Biocomput. NIH Public Access; 2014. p. 63–74. http://www.ncbi.nlm.nih.gov/pubmed/24297534. Accessed 21 June 2018.

43. Tatlow P, Piccolo SR. A cloud-based workflow to quantify transcript-expression levels in public cancer compendia. Sci Rep. 2016;6:39259.

44. TEAM RDC. Statutes of “The R Foundation for Statistical Computing” means to meet the objectives. 2005;1–5.

45. Subramanian A, Narayan R, Consello SM, Peck DO, Natoli TE, Lu X, et al. A next-generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171:1437–1452.e17.

46. Read Rectangular Text Data [R package readr version 1.1.1]. Comprehensive R Archive Network (CRAN). https://cran.r-project.org/web/packages/readr/index.html. Accessed 7 June 2018.

47. A Grammar of Data Manipulation [R package dplyr version 0.7.5]. Comprehensive R Archive Network (CRAN). https://cran.r-project.org/web/packages/dplyr/index.html. Accessed 7 June 2018.

48. Wickham H. Reshaping data with the reshape package. 2006. http://had.co.nz/reshape. Accessed 7 June 2018.

49. Barter RL, Yu B. Superheat: An R package for creating beautiful and extendable heatmaps for visualizing complex data. 2015. http://arxiv.org/abs/1512.01524.

50. Daley-Brown D, Oprea-Ilies G, Quashie A, Gonzalez-Perez RR. Emerging biomarkers and clinical implications in endometrial carcinoma. In: Role of Biomarkers in Medicine; 2016. http://www.intechopen.com/books/role-of-biomarkers-in-medicine/emerging-biomarkers-and-clinical-implications-in-endometrial-carcinoma. Accessed 4 June 2018.

51. Banno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, et al. Biomarkers in endometrial cancer: possible clinical applications (review). Oncol Lett. 2017;3:1175–80.

52. Perez I, Castro D, Bruniisma W, Reboutier D, Guarguaglini G, Asteriti IA, et al. Cross-talk between AURKA and PLK1 in mitotic entry and spindle assembly. Front Oncol. 2015;5:283. https://doi.org/10.3389/fonc.2015.00283.